{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.464.1003.198.11.1142","meta":{"versionId":"6","lastUpdated":"2019-03-15T01:00:14.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"NCQA PHEMUR Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2019-03-15"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1142","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.464.1003.198.11.1142"}],"version":"20190315","name":"OpiateAntagonists","title":"Opiate Antagonists","status":"active","experimental":false,"date":"2019-03-15T01:00:14-04:00","publisher":"NCQA PHEMUR","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: )","compose":{"include":[{"system":"http://www.cms.gov/Medicare/Coding/ICD10","concept":[{"code":"HZ90ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Nicotine Replacement"},{"code":"HZ91ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Methadone Maintenance"},{"code":"HZ92ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Levo-alpha-acetyl-methadol (LAAM)"},{"code":"HZ93ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Antabuse"},{"code":"HZ94ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Naltrexone"},{"code":"HZ95ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Naloxone"},{"code":"HZ96ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Clonidine"},{"code":"HZ97ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Bupropion"},{"code":"HZ98ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication"},{"code":"HZ99ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication"}]}]},"expansion":{"identifier":"urn:uuid:2ad08799-a257-4276-a791-cb25a72d40f7","timestamp":"2023-12-11T02:39:41-05:00","total":10,"contains":[{"system":"http://www.cms.gov/Medicare/Coding/ICD10","version":"2024","code":"HZ90ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Nicotine Replacement"},{"system":"http://www.cms.gov/Medicare/Coding/ICD10","version":"2024","code":"HZ91ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Methadone Maintenance"},{"system":"http://www.cms.gov/Medicare/Coding/ICD10","version":"2024","code":"HZ92ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Levo-alpha-acetyl-methadol (LAAM)"},{"system":"http://www.cms.gov/Medicare/Coding/ICD10","version":"2024","code":"HZ93ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Antabuse"},{"system":"http://www.cms.gov/Medicare/Coding/ICD10","version":"2024","code":"HZ94ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Naltrexone"},{"system":"http://www.cms.gov/Medicare/Coding/ICD10","version":"2024","code":"HZ95ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Naloxone"},{"system":"http://www.cms.gov/Medicare/Coding/ICD10","version":"2024","code":"HZ96ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Clonidine"},{"system":"http://www.cms.gov/Medicare/Coding/ICD10","version":"2024","code":"HZ97ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Bupropion"},{"system":"http://www.cms.gov/Medicare/Coding/ICD10","version":"2024","code":"HZ98ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication"},{"system":"http://www.cms.gov/Medicare/Coding/ICD10","version":"2024","code":"HZ99ZZZ","display":"Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication"}]}}